Urinary mi-106a for the diagnosis of IgA nephropathy: Liquid biopsy for kidney disease

Szeto, Cheuk‐Chun; Ng, Jack Kit‐Chung; Fung, Winston Wing‐Shing; Chan, Gcf; Luk, Cathy Choi-Wan; Lai, Ka-Bik; Wang, Gang; Chow, Kai‐Ming; Lai, Fernand Mac‐Moune

doi:10.1016/j.cca.2022.03.006

Cited by 6 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urinary microRNA (mi-106a) has been found to be a potential liquid biomarker for immunoglobulin A (IgA) nephropathy, a post-infectious nephritic syndrome associated with hematuria and proteinuria. IgA nephropathy was found to be associated with six miRNA targets, all of which were significantly elevated throughout the disease progression, indicating that these markers can provide excellent sensitivity for the detection of the disease ( 52 ). A research study regarding the urinary miRNA profile for the diagnosis of IgA nephropathy identified 39 miRNA and found that urinary mi-204 had the best diagnostic accuracy.…”

Section: Liquid Biopsy and Biomarkers In Kidney Diseasesmentioning

confidence: 99%

Liquid biopsy for non-invasive monitoring of patients with kidney transplants

Nassar,

Cashman,

Rao

et al. 2023

Front. Transplant.

View full text Add to dashboard Cite

The current tools for diagnosing and monitoring native kidney diseases as well as allograft rejection in transplant patients are suboptimal. Creatinine and proteinuria are non-specific and poorly sensitive markers of injury. Tissue biopsies are invasive and carry potential complications. In this article, we overview the different techniques of liquid biopsy and discuss their potential to improve patients’ kidney health. Several diagnostic, predictive, and prognostic biomarkers have been identified with the ability to detect and monitor the activity of native kidney diseases as well as early and chronic allograft rejection, such as donor-derived cell-free DNA, exosomes, messenger RNA/microsomal RNA, proteomics, and so on. While the results are encouraging, additional research is still needed as no biomarker appears to be perfect for a routine application in clinical practice. Despite promising advancements in biomarkers, the most important issue is the lack of standardized pre-analytical criteria. Large validation studies and uniformed standard operating procedures are required to move the findings from bench to bedside. Establishing consortia such as the Liquid Biopsy Consortium for Kidney Diseases can help expedite the research process, allow large studies to establish standardized procedures, and improve the management and outcomes of kidney diseases and of kidney transplant recipients.

show abstract

Section: Liquid Biopsy and Biomarkers In Kidney Diseasesmentioning

confidence: 99%